- Home
- FE vs MIRM Comparison
FE vs MIRM Comparison
Compare FE & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FE
- MIRM
- Stock Information
- Founded
- FE 1996
- MIRM 2018
- Country
- FE United States
- MIRM United States
- Employees
- FE N/A
- MIRM N/A
- Industry
- FE Electric Utilities: Central
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- FE Utilities
- MIRM Health Care
- Exchange
- FE Nasdaq
- MIRM Nasdaq
- Market Cap
- FE 23.9B
- MIRM 3.3B
- IPO Year
- FE N/A
- MIRM 2019
- Fundamental
- Price
- FE $43.08
- MIRM $73.79
- Analyst Decision
- FE Buy
- MIRM Strong Buy
- Analyst Count
- FE 16
- MIRM 10
- Target Price
- FE $46.14
- MIRM $74.20
- AVG Volume (30 Days)
- FE 3.2M
- MIRM 699.8K
- Earning Date
- FE 10-28-2025
- MIRM 11-11-2025
- Dividend Yield
- FE 4.13%
- MIRM N/A
- EPS Growth
- FE 49.18
- MIRM N/A
- EPS
- FE 2.27
- MIRM N/A
- Revenue
- FE $13,864,000,000.00
- MIRM $429,161,000.00
- Revenue This Year
- FE $8.73
- MIRM $53.08
- Revenue Next Year
- FE $3.41
- MIRM $20.45
- P/E Ratio
- FE $19.01
- MIRM N/A
- Revenue Growth
- FE 6.52
- MIRM 62.33
- 52 Week Low
- FE $37.58
- MIRM $36.86
- 52 Week High
- FE $44.78
- MIRM $78.10
- Technical
- Relative Strength Index (RSI)
- FE 46.98
- MIRM 61.09
- Support Level
- FE $42.87
- MIRM $73.35
- Resistance Level
- FE $43.93
- MIRM $76.87
- Average True Range (ATR)
- FE 0.48
- MIRM 2.38
- MACD
- FE -0.09
- MIRM -0.82
- Stochastic Oscillator
- FE 19.81
- MIRM 30.84
About FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with 10 regulated distribution utilities across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.